Atricure, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on January 1, 2007, and January 2, 2007, for Atricure, Inc., a Delaware corporation. The filing primarily addresses material changes in executive leadership and the entry into a definitive consulting agreement.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed relates to executive compensation under a new agreement:
- Consulting Compensation: $12,000 per month for Michael D. Hooven.
Material Changes
The report details two significant personnel transitions:
- Michael D. Hooven (Co-Founder and CTO): Transitioned from an operating role to a consultant effective January 1, 2007. He remains a director. The new Consulting Agreement requires 20 hours of service per week focused on new product development for cardiac arrhythmias and stroke prevention. The agreement includes a one-year term (ending December 31, 2007) and non-compete/non-solicitation restrictions until December 31, 2009.
- Stephen S. Cambridge (Vice President, Sales): Retired effective January 2, 2007. His responsibilities are being assumed by existing personnel.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or management commentary regarding future performance. The primary risk disclosed is the potential impact of leadership changes, though the company notes that Mr. Hooven will continue to advise on product development and Mr. Cambridge's duties are being absorbed internally. The consulting agreement automatically terminates upon a change of control event.
Investor Verification Checklist
- Review the full text of the Consulting Agreement (Exhibit 10.1) for specific intellectual property assignment terms and non-compete scope.
- Verify the identity and qualifications of the "existing personnel" assuming Mr. Cambridge's sales responsibilities.
- Monitor subsequent filings for any impact of these leadership changes on product development timelines or sales performance.